Nasdaq

European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer

Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3 Treatment with Phesgo is over 90% faster, ...
WebMD

What to Know About Herceptin for HER2

When you or a loved one has breast cancer, your doctor will figure out the best treatment options to offer you based on your particular tumor, your age, other conditions you have, and your wishes.
Nasdaq

Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE ...

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, ...
Medscape

Herceptin Associated With Significant Risk of Cardiotoxicity

Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...
Reuters

Chugai Pharmaceutical says lawsuit on patent infringement concerning Herceptin® injection and petition for provisional disposition order

* Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 ...
Reuters

Herceptin enhances Tykerb for breast cancer -study

LOS ANGELES, May 15 (Reuters) - A combination of targeted cancer drugs -- GlaxoSmithKline Plc's Tykerb and Genentech Inc's Herceptin -- works better than Tykerb alone in women with advanced breast ...
Business Wire

FDA Approves Genentech’s Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo™ ...
Business Insider

Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme ...

SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo ®, a fixed-dose combination of Perjeta ® ...